Image_3_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Image_2_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Image_1_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Serum levels of VEGF-C in ovarian cancer and non-cancer groups.

<p>Serum levels of VEGF-C in ovarian cancer and non-cancer groups.</p

Serum levels of VEGF-C in ovarian cancer patients in relation to clinic-pathological variables of tumor.

<p>Serum levels of VEGF-C in ovarian cancer patients in relation to clinic-pathological variables of tumor.</p

Characteristics of ovarian cancer patients.

<p>Characteristics of ovarian cancer patients.</p

Kaplan-Meier survival curves. Percent survival rate was stratified by VEGF-C level.

<p>Kaplan-Meier survival curves. Percent survival rate was stratified by VEGF-C level.</p

Association between IL-10 Gene Polymorphisms and Susceptibility of Tuberculosis: Evidence Based on a Meta-Analysis

<div><p>Background</p><p>A number of observational studies have been conducted to investigate the association of IL-10 gene polymorphisms with tuberculosis (TB) susceptibility. However, the results of different studies were inconsistent. The aim of this study was to investigate the relationship between IL-10 -1082G/A, -819T/C, and -592A/C polymorphisms and TB risk by meta-analysis.</p><p>Methods</p><p>A literature search was conducted among six English databases (PubMed, Embase, Web of Science, Science Direct, SpringerLink and EBSCO) and two Chinese databases (Wanfang and Chinese National Knowledge Infrastructure databases) to identify studies involving association between IL-10 −1082G/A, −819T/C, and −592A/C polymorphisms and TB susceptibility before May. 2013. Statistical analysis was performed using Revman 5.0 and Stata 12.0.</p><p>Results</p><p>A total of 31 studies with 6,559 cases and 7,768 controls were included in this meta-analysis. The results showed that three polymorphisms (-1082G/A, -819T/C, and -592A/C) in the IL-10 gene were not associated with the risk of TB in general population. In the subgroup analysis by ethnicity, IL-10 -1082G/A polymorphism was associated with TB risk in Europeans (AA+AG vs. GG: OR =  0.57, 95% CI = 0. 0.37–0.89, <i>P</i> = 0.01) and Americans (AA+AG vs. GG: OR =  0.39, 95% CI = 0.27–0.57, <i>P</i><0.01), and IL-10 -819T/C (C allele vs. T allele: OR = 0.83, 95% CI = 0.72–0.96, <i>P</i> = 0.01) and -592A/C (CC+AC vs. AA: OR =  0.65, 95% CI = 0.49–0.85, <i>P</i> = 0.002) polymorphisms were significantly associated with TB risk in Asians.</p><p>Conclusion</p><p>This meta-analysis provides strong evidence that IL-10-1082G/A polymorphism was associated with TB risk in Europeans and Americans, and IL-10 -819T/C and -592A/C polymorphisms could be risk factors for TB in Asians. Additional well designed large studies were required for the validation of our results.</p></div

Baseline characteristics of the 31 eligible studies for the analysis of IL-10 polymorphism.

<p>Baseline characteristics of the 31 eligible studies for the analysis of IL-10 polymorphism.</p

Determination of the genetic effects of <b><i>IL-10</i></b> polymorphisms on TB and subgroup analysis.

<p>Determination of the genetic effects of <b><i>IL-10</i></b> polymorphisms on TB and subgroup analysis.</p